# Alexander R. Lyon

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/alexander-r-lyon/

## Facts

| Field | Value |
| --- | --- |
| Citations | 71,493 |
| Field | Chemotherapy-induced cardiotoxicity and mitigation |
| h-index | 83 |
| i10-index | 208 |
| Last Known Institution | Royal Brompton Hospital |
| OpenAlex ID | https://openalex.org/A5063519328 |
| ORCID iD | https://orcid.org/0000-0001-8026-840X |
| Works | 387 |

## Researcher papers

Showing 12 of 14.

- [2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)](https://scholariq.org/papers/2022-esc-guidelines-on-cardio-oncology-developed-in-collaboration-with-the-2/)
- [2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure](https://scholariq.org/papers/2023-focused-update-of-the-2021-esc-guidelines-for-the-diagnosis-and-treatment/)
- [2020 ESC Guidelines for the management of adult congenital heart disease](https://scholariq.org/papers/2020-esc-guidelines-for-the-management-of-adult-congenital-heart-disease/)
- [2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure](https://scholariq.org/papers/2021-esc-guidelines-for-the-diagnosis-and-treatment-of-acute-and-chronic-heart-2/)
- [International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology](https://scholariq.org/papers/international-expert-consensus-document-on-takotsubo-syndrome-part-i-clinical/)
- [Current State of knowledge on Takotsubo Syndrome: A Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology](https://scholariq.org/papers/current-state-of-knowledge-on-takotsubo-syndrome-a-position-statement-from-the/)
- [Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations](https://scholariq.org/papers/management-of-cardiac-disease-in-cancer-patients-throughout-oncological/)
- [Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society](https://scholariq.org/papers/baseline-cardiovascular-risk-assessment-in-cancer-patients-scheduled-to-receive/)
- [Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement](https://scholariq.org/papers/defining-cardiovascular-toxicities-of-cancer-therapies-an-international-cardio/)
- [Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial](https://scholariq.org/papers/calcium-upregulation-by-percutaneous-administration-of-gene-therapy-in-patients/)
- [2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)](https://scholariq.org/papers/2022-esc-guidelines-on-cardio-oncology-developed-in-collaboration-with-the/)
- [Epidemiology, Pathophysiology and Contemporary Management of Cardiogenic Shock – A Position Statement from the Heart Failure Association of the European Society of Cardiology](https://scholariq.org/papers/epidemiology-pathophysiology-and-contemporary-management-of-cardiogenic-shock-a/)

## Researcher topics

- [Chemotherapy-induced cardiotoxicity and mitigation](https://scholariq.org/topics/chemotherapy-induced-cardiotoxicity-and-mitigation/)
- [Cardiac Imaging and Diagnostics](https://scholariq.org/topics/cardiac-imaging-and-diagnostics/)
- [Takotsubo Cardiomyopathy and Associated Phenomena](https://scholariq.org/topics/takotsubo-cardiomyopathy-and-associated-phenomena-2/)
- [Cardiovascular Function and Risk Factors](https://scholariq.org/topics/cardiovascular-function-and-risk-factors/)
- [Cardiac electrophysiology and arrhythmias](https://scholariq.org/topics/cardiac-electrophysiology-and-arrhythmias/)

## Researcher university

- [Royal Brompton Hospital](https://scholariq.org/institutions/royal-brompton-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.